Sangamo BioSciences | SGMO - Zahlungsmittel Und Äquivalente





Zahlungsmittel Und Äquivalente Veränderung Datum
Alaunos Therapeutics USD 354K 1.03M 2026-03
Alnylam Pharmaceuticals USD 1.71B 2.46M 2026-06
Alterity Therapeutics Limited AUD 15.77M 9.56M 2023-06
Amgen USD 13.99B 1.95B 2026-06
Bayer EUR 4.29B 1.44B 2026-06
BioCryst Pharmaceuticals USD 154.97M 16.62M 2026-06
Biogen USD 1.28B 2.1B 2026-06
BioMarin Pharmaceutical USD 874M 1.35B 2026-06
Cipla INR 10.18B 2.22B 2026-03
Clal Biotechnology ILS 5.73M 1.71M 2023-12
Compugen USD 12.43M 78.16M 2026-03
CSL USD 2.16B 633M 2025-06
Gilead Sciences USD 7.63B 64M 2026-03
GlaxoSmithKline GBP 3.44B 292M 2026-03
Grifols EUR 979.78M 334.84M 2024-12
Ionis Pharmaceuticals USD 350.06M 1.57B 2026-06
J&J USD 20.42B 1.27B 2026-06
Karyopharm Therapeutics USD 90.85M 30.31M 2026-03
Merck USD 6.85B 1.52B 2026-06
Novartis USD 7.62B 739M 2026-06
Omeros USD 1.9M 2.36M 2025-06
Pfizer USD 976M 727M 2026-06
Roche Holding CHF 7.55B 579M 2025-06
Sangamo BioSciences USD 38.34M 13.16M 2025-06
Sanofi EUR 6.35B 806M 2026-06
Sarepta Therapeutics USD 571.15M 106.7M 2026-06
Tectonic Therapeutic USD 236.89M 16.9M 2026-03
Ultragenyx Pharmaceutical USD 125M 50M 2026-06
Vertex Pharmaceuticals USD 7.85B 605.7M 2026-06